NRX PHARMACEUTICALS INC

NRXP shares slump 8.8% as the drug‑dev company faces a near 52‑week low, but a 200‑day SMA suggests short‑term recovery could hinge on new clinical data.

Explore Nrx Pharmaceuticals’ current 2.48$ price, pipeline prospects, and peer comparison—what’s driving its 20% decline and future catalyst?

NRXP shares rise 1.15% to $2.62 amid 24‑hour trading data, market cap $112.5M, and peer comparison—discover the latest performance insights.

NRX Pharmaceuticals (NRXP) stalls as investors seek clinical milestones and partnerships; its stock lags peers and remains below the 200‑day average.